Edgewise Therapeutics Reports 2-Month Interim Results of EDG-5506 in P-Ib (ARCH) Study for the Treatment of Becker Muscular Dystrophy
Shots:
- The ongoing P-Ib (ARCH) study evaluates the safety, tolerability, impact on muscle damage biomarkers & PK of EDG-5506 (10mg, qd) in 12 adult males with BMD
- The results showed a lowered muscle damage biomarker, reduction of CK & fast skeletal muscle troponin I (TNNI2) by 30% & 68% after 2mos., reduced exposure for BMD patients which was consistent with the lower dose of 10mg, shorter half-life associated with a decreased overall muscle mass. The therapy was transient & typically observed in the first few days of dosing
- Additionally, patients were more active during 2mos. of dosing with EDG-5506 relative to activity measured in the P-I study, well-tolerated with no discontinuations or dose reductions
Ref: Bussinesswire | Image: Edgewise Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
